Revvity, Inc. (NYSE: RVTY)
Health Care · Life Sciences Tools & Services · US
$124.75
+0.50% today · +39.1% 1Y
Revvity, Inc. (NYSE: RVTY) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $13.92B and employs 11,000 people.
Over the last twelve months the share price has gained 39.1%, trading between 81.22 and 124.49.
Tweenvest scores Revvity, Inc. across four factors: quality 67/100, value 33/100, growth 10/100, dividend 29/100. Its strongest factor is quality.
RVTY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.92B
- Revenue (TTM)
- $2.91B
- P/E
- 59.60
- EPS
- 2.09
- Dividend yield
- 0.23%
- Beta (5Y)
- 1.07
- 52-week high
- $124.49
- 52-week low
- $81.22
- Avg volume (3M)
- —
- Shares outstanding
- 111.59M
- Employees
- 11,000
- Next earnings
- —
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- ISIN
- US7140461093
- Founded
- 1937
- Listed since
- Jul 6, 1965
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $629.27 | +0.27% |
| Danaher CorporationNYSE: DHR | $153.85B | $218.85 | +1.36% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF592.20 | +1.09% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $159.00 | +1.73% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $259.82 | +1.47% |
| Waters CorporationNYSE: WAT | $40.35B | $410.70 | +1.49% |
Figures last refreshed Aug 18, 2026.